Inovio Pharmaceuticals, Inc.
INOHealthcare|Biotechnology|US
$1.22
-0.23 (-16.21%)
DCF Value
$0.69
Tangible Book / Share
$0.05
Cash / Share
$0.45
Clinical Trials (54)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03491683 INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | Glioblastoma | P1P2 | Active | 52 | Open-label | INO-5401, INO-9012, Cemiplimab, Temozolomide |
| NCT04367675 INO 5401 Vaccination in BRCA1/2 Mutation Carriers | BRCA1/2 Mutation | P1 | Active | 44 | Open-label | INO-5401, INO-9012 |
| NCT02772003 DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection | Chronic Hepatitis, Hepatitis C Infection | P1 | Active | 33 | Single-blind | Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Rocakinogene Sifuplasmid |
| NCT00198263 Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer | Head and Neck Cancer | P4 | Completed | 95 | Open-label | — |
| NCT00198276 Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer | Cancer | P4 | Completed | 88 | Open-label | — |
| NCT03185013 REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion | P3 | Completed | 201 | RCT, Double-blind | VGX-3100, Placebo |
| NCT00198315 Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma | Head and Neck Cancer | P3 | Terminated | 130 | RCT, Open-label | — |
| NCT04642638 Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure | Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | P2P3 | Terminated | 1,307 | RCT, Double-blind | INO-4800, Placebo |
| NCT03721978 REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion | P3 | Completed | 203 | RCT, Double-blind | VGX-3100, Matched Placebo |
| NCT00198328 Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma | Head Neck Cancer | P3 | Terminated | 84 | RCT, Open-label | — |
| NCT03721718 Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers | Healthy | P1P2 | Completed | 60 | RCT, Open-label | GLS-5300 |
| NCT03499795 VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 | Anal Neoplasm | P2 | Completed | 23 | Open-label | VGX-3100 |
| NCT02172911 A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer | Cervical Cancer | P1P2 | Completed | 10 | Open-label | INO-3112 |
| NCT01335711 CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects | Chronic Hepatitis C | P2 | Unknown | 32 | RCT, Open-label | ChronVac-C + SOC, SOC |
| NCT02163057 Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Cancer | P1P2 | Completed | 22 | Open-label | INO-3112 |
| NCT03603808 VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions | Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia | P2 | Completed | 44 | Open-label | HPV DNA Plasmids Therapeutic Vaccine VGX-3100 |
| NCT03606213 Therapeutic Vaccination in Treated HIV Disease | HIV-1-infection | P1P2 | Completed | 56 | RCT, Single-blind | PENNVAX-GP, INO-6145, INO-9012 |
| NCT04588428 Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | P2 | Completed | 192 | RCT, Double-blind | INO-4700, Placebo, INO-4700 |
| NCT02501278 A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer | Uterine Cervical Neoplasms | P2 | Withdrawn | — | RCT, Open-label | INO-3112 vaccine, Cisplatin chemotherapy |
| NCT04447781 Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 | Coronavirus Infection, SARS-CoV 2 | P1P2 | Completed | 79 | RCT, Double-blind | INO-4800 |
| NCT01334060 WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation | Leukaemia (Acute), Leukaemia (Chronic) | P2 | Completed | 23 | Open-label | p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine |
| NCT01304524 A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 | Cervical Intraepithelial Neoplasia | P2 | Completed | 167 | RCT, Double-blind | VGX 3100, Placebo |
| NCT03180684 Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia | P2 | Completed | 33 | RCT, Open-label | VGX-3100, Imiquimod 5% Cream |
| NCT04398433 INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) | Respiratory Papillomatosis | P1P2 | Completed | 32 | Open-label | INO-3107 |
| NCT00563173 Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients | Chronic Hepatitis C Virus Infection | P1P2 | Unknown | 12 | Open-label | CHRONVAC-C® |
| NCT03502785 INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | Urothelial Carcinoma | P1P2 | Completed | 35 | Open-label | INO-5401, INO-9012, Atezolizumab |
| NCT02809443 GLS-5700 in Dengue Virus-Naïve Adults | Healthy | P1 | Completed | 40 | Open-label | GLS-5700 |
| NCT02670187 Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers | Healthy | P1 | Completed | 75 | Open-label | GLS-5300 |
| NCT03835533 Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations | Metastatic Castration-resistant Prostate Cancer | P1 | Completed | 43 | Open-label | NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C) |
| NCT02027116 Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection | Hepatitis C, Chronic | P1 | Completed | 18 | Open-label | VGX-6150 |
| NCT03674125 Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection | HCV Infection | P1 | Completed | 32 | RCT, Open-label | GLS-6150 |
| NCT01184976 Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males | Healthy | P1 | Completed | 30 | Open-label | VGX-3400 |
| NCT02464670 Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers | Ebola Vaccine | P1 | Completed | 240 | RCT, Double-blind | INO-4201, INO-4202, INO-4201, INO-4212, INO-4212 + INO-9012, INO-4201 + INO-9012 |
| NCT02887482 GLS-5700 in Dengue Virus Seropositive Adults | Healthy, Zika | P1 | Completed | 160 | RCT, Double-blind | GLS-5700, Placebo |
| NCT01082692 Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants | HIV-1 Infection, HIV Infections | P1 | Completed | 12 | Open-label | PENNVAX-B |
| NCT02241369 Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies | Aerodigestive Precancerous Lesions and Malignancies | P1 | Completed | 3 | Open-label | INO-3106, INO-9012 |
| NCT01188850 Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100 | Human Papillomavirus (HPV) | P1 | Completed | 14 | Open-label | VGX-3100 |
| NCT03831503 A Study of INO-A002 in Healthy Dengue Virus-naive Adults | Healthy Volunteers | P1 | Completed | 30 | Open-label | INO-A002 |
| NCT04906629 INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees | Ebola Virus Disease | P1 | Completed | 46 | RCT, Double-blind | INO-4201, Placebo |
| NCT02431312 Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects | Hepatitis B | P1 | Completed | 90 | RCT, Open-label | INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment |
| NCT03805984 Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers | Lassa Fever | P1 | Completed | 60 | RCT, Double-blind | INO-4500, Placebo |
| NCT01403155 A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 | Healthy | P1 | Completed | 22 | Open-label | INO-3401 + EP |
| NCT00685412 Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 | Papillomavirus Infections | P1 | Completed | 18 | Open-label | VGX-3100 |
| NCT02514213 Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer | Prostate Cancer | P1 | Completed | 62 | Open-label | 2mg INO-5150 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 and electroporation device CELLECTRA®-5P, 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P |
| NCT01142362 Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults | Healthy | P1 | Completed | 32 | Open-label | VGX-3400X |
| NCT02960594 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Breast Cancer, Lung Cancer | P1 | Completed | 93 | Open-label | INO-1400, INO-9012, INO-1401 |
| NCT04336410 Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | Coronavirus Infection | P1 | Completed | 120 | Open-label | INO-4800 |
| NCT01587131 DNA-based Influenza Vaccine in the Elderly | Influenza, Human, Orthomyxoviridae Infections | P1 | Completed | 50 | RCT, Open-label | FVH1 - a DNA-based influenza vaccine |
| NCT05293249 dMAbs for Prevention of COVID-19 | Healthy Volunteers | P1 | Completed | 61 | Open-label | Hylenex |
| NCT01405885 A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus | Healthy | P1 | Completed | 116 | Open-label | INO-3605, INO-3609, INO-3401, INO-3609, INO-3605 AND INO-3609, INO-3510, INO-3609, INO-3609, Seasonal Influenza vaccine, INO-3609 |
| NCT00721461 A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001) | Healthy | P1 | Completed | 24 | Open-label | V930 |
| NCT04093076 Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana | Lassa Fever | P1 | Completed | 220 | RCT, Double-blind | INO-4500, Placebo |
| NCT05430958 Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers | Coronavirus Infection | P1 | Withdrawn | — | Open-label | INO-4800, INO-9112 |
| NCT05781542 Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV | HIV Infections | P1 | Completed | 46 | RCT, Open-label | sD-NP-GT8 DNA, sD-NP-GT8 DNA, IL-12 DNA, IL-12 DNA, Trimer 4571, 3M-052-AF, Alum |